{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T12:03:05Z","timestamp":1772452985001,"version":"3.50.1"},"reference-count":40,"publisher":"FapUNIFESP (SciELO)","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82202890"],"award-info":[{"award-number":["82202890"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Braz J Med Biol Res"],"abstract":"<jats:p>Proteinuria is a prevalent and significant adverse response (ADR) associated with numerous pharmaceuticals, and we employed the online public FDA Adverse Event Reporting System (FAERS) database to investigate a cohort of medications that may induce this ADR. This analysis aimed to identify and assess the most prevalent and significant medicines linked to the risk of proteinuria. We examined the publicly accessible FAERS database from 2004 to 2024. Utilizing the search term \u201cproteinuria\u201d and classifying by generic drug name, we aggregated reports of drug-related responses or trends in proteinuria, subsequently analyzing the data through a combination of ratio-of-reported-ratio (ROR) and proportional-reported-ratio (PRR) to identify and examine twelve medications that may induce proteinuria. A total of 16,355 adverse event reports related to proteinuria were identified in the FAERS database between 2004 and 2024. Among these, 21 drugs demonstrated statistically significant associations with proteinuria based on multivariate logistic regression, with the highest signals observed for voclosporin (ROR: 63.57) and lenvatinib (ROR: 41.01). Drug classes most strongly associated included anticancer agents, immunosuppressants, and antiviral drugs. Notably, the onset of proteinuria varied significantly across drug types, with anti-inflammatory agents showing the earliest median onset (5.4 days), while digestive system drugs and antivirals exhibited delayed onset exceeding 1,000 days on average. These findings underscore the need for early and long-term renal monitoring depending on drug category. Prompt assessment of nephrotoxicity risk is essential during the initial phase of medication, hence offering a more precise foundation for drug screening and optimization.<\/jats:p>","DOI":"10.1590\/1414-431x2025e15097","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T11:11:37Z","timestamp":1772449897000},"source":"Crossref","is-referenced-by-count":0,"title":["Drug-related proteinuria: a vigilance analysis based on the FAERS database"],"prefix":"10.1590","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7272-9417","authenticated-orcid":false,"given":"Zhixiang","family":"Mao","sequence":"first","affiliation":[{"name":"Affiliated Hospital of Xuzhou Medical University,  China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1879-4521","authenticated-orcid":false,"given":"Linjian","family":"Zhou","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Xuzhou Medical University,  China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0805-7901","authenticated-orcid":false,"given":"Yi","family":"Nie","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Xuzhou Medical University,  China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6480-5540","authenticated-orcid":false,"given":"Hongbing","family":"Wang","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Xuzhou Medical University,  China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1554-0339","authenticated-orcid":false,"given":"Junying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Jiangsu Cancer Hospital,  China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2026]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"117675","DOI":"10.1016\/j.cca.2023.117675","article-title":"Proteinuria selectivity index in renal disease","volume":"552","author":"Liu W","year":"2024","journal-title":"Clin Chim Acta Int J Clin Chem"},{"issue":"4","key":"ref2","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00467-019-04454-w","article-title":"Proteinuria-take a closer look!","volume":"35","author":"B\u00f6kenkamp A","year":"2020","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"ref3","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-term outcomes in IgA nephropathy","volume":"18","author":"Pitcher D","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"ref4","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/ndt\/gfae009","article-title":"Outcome of immunosuppression in children with IgA vasculitis-related nephritis","volume":"39","author":"Rohner K","year":"2024","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"ref5","doi-asserted-by":"crossref","first-page":"94432","DOI":"10.5409\/wjcp.v13.i3.94432","article-title":"Evaluation of thyroid profile among children aged 1-15 years with nephrotic syndrome: an observation study","volume":"13","author":"Kumari P","year":"2024","journal-title":"World J Clin Pediatr"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1196793","DOI":"10.3389\/fimmu.2023.1196793","article-title":"Severe and fatal adverse events of immune checkpoint inhibitor combination therapy in patients with metastatic renal cell carcinoma: a systematic review and meta-analysis","volume":"14","author":"Feng YN","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12882-020-01836-3","article-title":"Glomerulonephritis histopathological pattern change","volume":"21","author":"AlYousef A","year":"2020","journal-title":"BMC Nephrol"},{"issue":"10","key":"ref8","first-page":"CD007004","article-title":"Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease","volume":"10","author":"Chung EY","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"ref9","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.2215\/CJN.11290821","article-title":"Drug-induced acute kidney injury","volume":"17","author":"Perazella MA","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10302","key":"ref10","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0140-6736(21)00519-5","article-title":"Chronic kidney disease","volume":"398","author":"Kalantar-Zadeh K","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"ref11","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.2215\/CJN.15040920","article-title":"Long-term immunosuppression management: opportunities and uncertainties","volume":"16","author":"Wojciechowski D","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"ref12","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.3390\/ijms22116109","article-title":"The mechanism of drug nephrotoxicity and the methods for preventing kidney damage","volume":"22","author":"Kwiatkowska E","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS)","volume":"9","author":"Yu RJ","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"188391","DOI":"10.1016\/j.bbcan.2020.188391","article-title":"Lenvatinib for hepatocellular carcinoma: from preclinical mechanisms to anti-cancer therapy","volume":"1874","author":"Zhao Y","year":"2020","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1154771","DOI":"10.3389\/fonc.2023.1154771","article-title":"Impact of lenvatinib-induced proteinuria and renal dysfunction in patients with thyroid cancer","volume":"13","author":"Shibutani Y","year":"2023","journal-title":"Front Oncol"},{"issue":"2","key":"ref16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41416-021-01557-w","article-title":"Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients","volume":"126","author":"Quintanilha JCF","year":"2022","journal-title":"Br J Cancer"},{"issue":"6","key":"ref17","doi-asserted-by":"crossref","first-page":"e008475","DOI":"10.1136\/jitc-2023-008475","article-title":"Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: a single-arm, phase II trial","volume":"12","author":"Huang J","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"10","key":"ref18","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1093\/ckj\/sfab066","article-title":"Review of intravitreal VEGF inhibitor toxicity and report of collapsing FSGS with TMA in a patient with age-related macular degeneration","volume":"14","author":"Phadke G","year":"2021","journal-title":"Clin Kidney J"},{"issue":"14","key":"ref19","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.3390\/ijms21145051","article-title":"Podocytes-the most vulnerable renal cells in preeclampsia","volume":"21","author":"Kwiatkowska E","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"11","key":"ref20","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1093\/ndt\/gfae184","article-title":"Immune checkpoint inhibitor-associated nephritis-treatment standard","volume":"39","author":"Barbir EB","year":"2024","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"ref21","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/s41581-022-00630-8","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury","volume":"18","author":"Sprangers B","year":"2022","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"ref22","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ekir.2020.10.002","article-title":"A systematic review of immune checkpoint inhibitor-associated glomerular disease","volume":"6","author":"Kitchlu A","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"1","key":"ref23","first-page":"2046","article-title":"Glomerular diseases after immune checkpoint inhibitors use: what do we know so far?","volume":"44","author":"He X","year":"2022","journal-title":"Ren Fail"},{"issue":"12","key":"ref24","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1136\/gutjnl-2022-329147","article-title":"Targeting MS4A4A on tumour-associated macrophages restores CD8+ T-cell-mediated antitumour immunity","volume":"72","author":"Li Y","year":"2023","journal-title":"Gut"},{"issue":"4","key":"ref25","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2217\/imt-2020-0223","article-title":"Acute interstitial nephritis and PR3-ANCA following reintroduction of pembrolizumab: a case report","volume":"13","author":"Mulroy M","year":"2021","journal-title":"Immunotherapy"},{"issue":"12","key":"ref26","first-page":"e49883","article-title":"Impact of proton pump inhibitors on kidney function and chronic kidney disease progression: a systematic review","volume":"15","author":"Parmar MP","year":"2023","journal-title":"Cureus"},{"issue":"4","key":"ref27","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1053\/j.ajkd.2020.03.023","article-title":"NSAIDs in CKD: are they safe?","volume":"76","author":"Baker M","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"ref28","doi-asserted-by":"crossref","first-page":"100655","DOI":"10.1016\/j.trre.2021.100655","article-title":"An overview of the efficacy and safety of everolimus in adult solid organ transplant recipients","volume":"36","author":"Tedesco-Silva H","year":"2022","journal-title":"Transplant Rev (Orlando)"},{"issue":"1","key":"ref29","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/TP.0000000000004749","article-title":"A head-to-head comparison of de novo sirolimus or everolimus plus reduced-dose tacrolimus in kidney transplant recipients: a prospective and randomized trial","volume":"108","author":"Freschi JTR","year":"2024","journal-title":"Transplantation"},{"issue":"11","key":"ref30","first-page":"e48628","article-title":"Exemestane-everolimus-induced angioedema in a woman with metastatic breast cancer: a case report and review","volume":"15","author":"Grabie YY","year":"2023","journal-title":"Cureus"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejca.2023.03.024","article-title":"Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: real-world data","volume":"186","author":"Boil\u00e0ve A","year":"2023","journal-title":"Eur J Cancer"},{"issue":"5","key":"ref32","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.ackd.2021.08.001","article-title":"Conventional chemotherapy nephrotoxicity","volume":"28","author":"Gupta S","year":"2021","journal-title":"Adv Chronic Kidney Dis"},{"issue":"2","key":"ref33","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3947\/ic.2023.0001","article-title":"Incidence and risk factors of tenofovir disoproxil fumarate induced nephrotoxicity and renal function recovery, a hospital case-control study","volume":"55","author":"Srisopa S","year":"2023","journal-title":"Infect Chemother"},{"issue":"9","key":"ref34","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1097\/QAD.0000000000003916","article-title":"Safety of tenofovir alafenamide in people with HIV who experienced proximal renal tubulopathy on tenofovir disoproxil","volume":"38","author":"Campbell L","year":"2024","journal-title":"AIDS"},{"issue":"8","key":"ref35","doi-asserted-by":"crossref","first-page":"3000605231195469","DOI":"10.1177\/03000605231195469","article-title":"Fanconi syndrome induced by the long-term use of tenofovir disoproxil fumarate: a case report and literature review","volume":"51","author":"Li J","year":"2023","journal-title":"J Int Med Res"},{"issue":"10246","key":"ref36","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(20)31065-5","article-title":"Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial","volume":"396","author":"Mayer KH","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"ref37","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1007\/s00198-022-06499-4","article-title":"Renal safety of zoledronic acid for osteoporosis in adults 75 years and older","volume":"33","author":"Fixen CW","year":"2022","journal-title":"Osteoporos Int"},{"issue":"3","key":"ref38","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje N","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"ref39","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000527931","article-title":"Severe hypophosphatemia as the initial presentation of renal fanconi's syndrome and distal renal tubular acidosis related to zoledronic acid: a case report and literature review","volume":"48","author":"Wu Y","year":"2023","journal-title":"Kidney Blood Press Res"},{"issue":"1","key":"ref40","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S2352-4642(18)30350-X","article-title":"Renal function abnormalities and deferasirox","volume":"3","author":"Kattamis A","year":"2019","journal-title":"Lancet Child Adolesc Health"}],"container-title":["Brazilian Journal of Medical and Biological Research"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_pdf&pid=S0100-879X2026000103815&tlng=en","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T11:11:43Z","timestamp":1772449903000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0100-879X2026000103815&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":40,"alternative-id":["S0100-879X2026000103815"],"URL":"https:\/\/doi.org\/10.1590\/1414-431x2025e15097","relation":{},"ISSN":["1414-431X","0100-879X"],"issn-type":[{"value":"1414-431X","type":"electronic"},{"value":"0100-879X","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"e15097"}}